Optimisation of bioluminescent reporters for use with mycobacteria.

Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. · 2010

Read Optimisation of bioluminescent reporters for use with mycobacteria. by Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2875389.txt.

Introduction

Andreu and colleagues tuned in 2010 glowing reporter genes so tuberculosis bacteria can be tracked inside living animals without surgery. The reporters are luciferases, enzymes that make light, borrowed from fireflies, sea creatures, and bacteria. Light output had been too dim through tissue, so the team tested vector, promoter, and gene spelling combinations to raise it.

They achieved the first working expression of the full bacterial light operon in the tuberculosis germ and in a fast-growing relative. That version needs no added fuel chemical, since the bacteria make their own. Other tuned versions shone brightly enough for external imaging as well. Brighter, self-lit bacteria open the way to watching infection and drug action in the same animal over time.

Catalog record

CREATORAndreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2875389

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Optimisation of Bioluminescent Reporters for Use with Mycobacteria By Nuria Andreu, Andrea Zelmer, Taryn Fletcher, Paul T. Elkington, Theresa H. Ward, Jorge Ripoll, Tanya Parish, Gregory J. Bancroft, Ulrich Schaible, Brian D. Robertson, Siouxsie Wiles, T. Mark Doherty Published in: PLoS ONE DOI: 10.1371/journal.pone.0010777 ABSTRACT Background Mycobacterium tuberculosis, the causative agent of tuberculosis, still represents a major public health threat in many countries. Bioluminescence, the production of light by luciferase-catalyzed reactions, is a versatile reporter technology with multiple applications both in vitro and in vivo. In vivo bioluminescence imaging (BLI) represents one of its most outstanding uses by allowing the non-invasive localization of luciferase-expressing cells within a live animal. Despite the extensive use of luminescent reporters in mycobacteria, the resultant luminescent strains have not been fully applied to BLI. Methodology/Principal Findings One of the main obstacles to the use of bioluminescence for in vivo imaging is the achievement of reporter protein expression levels high enough to obtain a signal that can be detected externally. Therefore, as a first step in the application of this technology to the study of mycobacterial infection in vivo, we have optimised the use of firefly, Gaussia and bacterial luciferases in mycobacteria using a combination of vectors, promoters, and codon-optimised genes. We report for the first time the functional expression of the whole bacterial lux operon in Mycobacterium tuberculosis and M. smegmatis thus allowing the development of auto-luminescent mycobacteria. We demonstrate that the Gaussia luciferase is secreted from bacterial cells and that this secretion does not require a signal sequence. Finally we prove that the signal produced by recombinant mycobacteria expressing either the firefly or bacterial luciferases can be non-invasively detected in the lungs of infected mice by bioluminescence imaging. Conclusions/Significance While much work remains to be done, the finding that both firefly and bacterial luciferases can be detected non-invasively in live mice is an important first step to using these reporters to study the pathogenesis of M. tuberculosis and other mycobacterial species in vivo. Furthermore, the development of auto-luminescent mycobacteria has enormous ramifications for high throughput mycobacterial drug screening assays which are currently carried out either in a destructive manner using LuxAB or the firefly luciferase. INTRODUCTION Mycobacterium tuberculosis was first isolated more than 125 years ago. Although a huge amount of research has been devoted to it over this time, tuberculosis still represents a major public health threat in many countries [1]. The main hindrances in fighting this disease include a lack of understanding of the human infection, its establishment and progression, as well as the host-pathogen interactions that determine the different outcomes. Furthermore, the treatment regimen of six months administration of up to four drugs has not evolved in more than four decades, and recent years have seen an alarming increase in multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains. It is clear then that novel and imaginative approaches are needed to speed up both basic and translational research in tuberculosis, especially in the areas of vaccine and drug development. Bioluminescence, the production of light by luciferase-catalysed reactions, is a versatile reporter technology with multiple applications both in vitro and in vivo. In vivo bioluminescence imaging (BLI) represents one of its most outstanding uses by allowing the non-invasive localisation of luciferase-expressing cells within an animal. Applied to the study of infectious diseases, BLI permits the detection of microorganisms from within living animals thus allowing the spatiotemporal study of infection in real-time in the same host [2]. Moreover, using luciferase as a reporter of gene expression, it is possible to establish when and where a gene function is needed, shedding light on bacterial pathogenesis [3], [4], [5]. Finally, BLI constitutes an easy and rapid method to test novel antimicrobial compounds in vivo [6], [7]. Luciferases are a large family of enzymes that catalyse the oxidation of a substrate, generically called luciferin, to yield oxyluciferin with the concomitant production of light. Three main luciferin-luciferase systems have been utilised for BLI [8]. The first system is represented by the firefly luciferase (FFluc) from Photinus pyralis which uses D-luciferin (a benzothiazole) as substrate, is dependent on ATP and results in the production of yellow-green light (557 nm). The second system includes the luciferases from the marine organisms Renilla reniformis (a cnidarian) and Gaussia princeps (a copepod) and the substrate coelenterazine. The signal produced by the G. princeps luciferase (Gluc) has been reported to be stronger than that of FFluc [9], even though the light emitted is in the blue range (480 nm) and is therefore more susceptible to tissue absorption and scattering. The fact that Gluc is strongly resistant to heat and extreme pH [9], [10], and that it is secreted by eukaryotic cells also make this system very attractive. Bacterial luciferases, found in the terrestrial bacterium Photorhabdus luminescens and marine bacteria from the genera Vibrio and Photobacterium, constitute the third luciferin-luciferase system. These luciferases are heterodimeric enzymes that use FMNH2 and a long-chain aldehyde as substrates. Bacterial luciferases are encoded by the genes luxAB that form an operon (luxCDABE) together with three additional genes (luxCDE) whose products synthesise the long-chain aldehyde. The main advantage of this system is that it does not need exogenously added substrate, but again the light produced is in the blue range (490 nm). Bioluminescence has been used in mycobacterial research for more than 20 years. Initially, FFluc was used to measure ATP as an indirect method of assessing cell viability and cell numbers [11], [12]. Considering the long duplication times of mycobacteria, the advantages of using bioluminescence as a reporter to assay anti-mycobacterial agents soon became evident when compared to the more traditional colony count methods. To this end LuxAB (requiring the addition of exogenous substrate) and FFluc have been used in M. smegmatis, M. tuberculosis, M. bovis BCG, and even M. avium, M. intracellulare and M. aurum [13], [14], [15], [16], [17], [18], [19]. The development of luciferase reporter phages represented a further improvement as it enabled testing of the drug susceptibility of clinical strains and has subsequently been applied to tuberculosis diagnostics [20], [21], [22], [23], [24], [25], [26], [27]. Finally, luminescent reporter strains have also been used for antibiotic testing and immunity assessment in cell cultures and ex vivo in organ homogenates of infected mice [28], [29], [30], [31], [32], [33], [34], [35]. Despite the extensive use of luminescent reporters in mycobacteria, these have only recently been applied to the imaging of mycobacteria in vivo [36]. In the single published paper on BLI of mycobacteria, Heus and collaborators utilised a recombinant M. bovis BCG strain expressing luxAB to monitor mycobacteria infection in vivo. While the authors prove that BLI can be used to study bacterial dissemination, drug efficacy and the role of the immune response, their approach has some limitations. In fact, the authors failed to detect BCG in the lungs of infected mice despite being able to detect bacteria in these organs by colony counting and ex vivo imaging. Because their luminescent strain of BCG did not express the luxCDE genes for substrate synthesis, Heus and collaborators had to administer decanal to the mice in order to image the bacteria. This substrate is highly toxic and, although they were able to deliver it by injection into the

Read the complete text